Guidelines for the management of community-acquired pneumonia - Current recommendations and antibiotic selection issues

被引:31
作者
Niederman, MS
机构
[1] Winthrop Univ Hosp, Dept Med, Div Pulm & Crit Care Med, Mineola, NY 11501 USA
[2] SUNY Stony Brook, Dept Med, Stony Brook, NY 11794 USA
关键词
D O I
10.1016/S0025-7125(05)70392-8
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
In the past decade, several guidelines for community-acquired pneumonia (CAP) have been published by a variety of organizations. Each has its own focus and methodology, and this article summarizes and compares the existing guidelines, emphasizing newer guidelines and areas of consensus. A guideline focuses on many patient care issues, in addition to antibiotic selection, but when antibiotics are administered, certain principles must be followed, and these are discussed. The principles focus on the timing and selection of specific agents, the need to account for atypical pathogen infection in all patients, the strategies for dealing with drug-resistant organisms, and the way to incorporate new antimicrobial agents into daily practice. Guidelines are useful for CAP management, making care more organized and uniform and leading to measurable improvements in a variety of outcomes, including mortality and length of stay.
引用
收藏
页码:1493 / +
页数:18
相关论文
共 42 条
[1]   Pneumococcal macrolide resistance - myth or reality? [J].
Amsden, GW .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1999, 44 (01) :1-6
[2]   Community-acquired pneumonia in adults: Guidelines for management [J].
Bartlett, JG ;
Breiman, RF ;
Mandell, LA ;
File, TM .
CLINICAL INFECTIOUS DISEASES, 1998, 26 (04) :811-838
[3]  
Bartlett John G., 2000, Clinical Infectious Diseases, V31, P347, DOI 10.1086/313954
[4]   Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada [J].
Chen, DK ;
McGeer, A ;
de Azavedo, JC ;
Low, DE .
NEW ENGLAND JOURNAL OF MEDICINE, 1999, 341 (04) :233-239
[5]   Multivariate analysis of risk factors for infection due to penicillin-resistant and multidrug-resistant Streptococcus pneumoniae: A multicenter study [J].
ClavoSanchez, AJ ;
GironGonzalez, JA ;
LopezPrieto, D ;
CanuetoQuintero, J ;
SanchezPorto, A ;
VergaraCampos, A ;
MarinCasanova, P ;
CordobaDona, JA .
CLINICAL INFECTIOUS DISEASES, 1997, 24 (06) :1052-1059
[6]   Mortality from invasive pneumococcal pneumonia in the era of antibiotic resistance, 1995-1997 [J].
Feikin, DR ;
Schuchat, A ;
Kolczak, M ;
Barrett, NL ;
Harrison, LH ;
Lefkowitz, L ;
McGreer, A ;
Farley, MM ;
Vugia, DJ ;
Lexau, C ;
Stefonek, KR ;
Patterson, JE ;
Jorgensen, JH .
AMERICAN JOURNAL OF PUBLIC HEALTH, 2000, 90 (02) :223-229
[7]  
FINCH R, 1993, BRIT J HOSP MED, V49, P346
[8]   A prediction rule to identify low-risk patients with community-acquired pneumonia [J].
Fine, MJ ;
Auble, TE ;
Yealy, DM ;
Hanusa, BH ;
Weissfeld, LA ;
Singer, DE ;
Coley, CM ;
Marrie, TJ ;
Kapoor, WN .
NEW ENGLAND JOURNAL OF MEDICINE, 1997, 336 (04) :243-250
[9]   TREATMENT OF SEVERE PNEUMONIA IN HOSPITALIZED-PATIENTS - RESULTS OF A MULTICENTER, RANDOMIZED, DOUBLE-BLIND TRIAL COMPARING INTRAVENOUS CIPROFLOXACIN WITH IMIPENEM-CILASTATIN [J].
FINK, MP ;
SNYDMAN, DR ;
NIEDERMAN, MS ;
LEEPER, KV ;
JOHNSON, RH ;
HEARD, SO ;
WUNDERINK, RG ;
CALDWELL, JW ;
SCHENTAG, JJ ;
SIAMI, GA ;
ZAMECK, RL ;
HAVERSTOCK, DC ;
REINHART, HH ;
ECHOLS, RM ;
HELSMOORTEL, C ;
SOJASTRZEPA, D ;
SCHWAITZBERG, S ;
BAREFOOT, L ;
FEIN, AM ;
FEINSILVER, SH ;
ILOWITE, JS ;
CLARE, N ;
SCHULMAN, D ;
JONES, CB ;
GRIFFIN, RI ;
WROBEL, CW ;
BALLOW, CH ;
AMSDEN, G ;
MITCHELL, P ;
BESS, T ;
WILKINS, W ;
BROWN, RB ;
MCGEE, W ;
SAFFORD, MJ ;
LEVINE, DP ;
LERNER, SA ;
KRUSE, JA ;
BANDER, JJ ;
MCNEIL, P ;
MUNKARAH, M ;
SUMMER, WR ;
DEBOISBLANC, B ;
LEVISON, ME ;
KORZENIOWSKI, O ;
SIGLER, A ;
BALDASSARRE, J ;
WALSH, P ;
SAMEL, C ;
SESSLER, CN ;
POLK, RE .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1994, 38 (03) :547-557
[10]  
FISHMAN NO, 1999, 39 INT C ANT AG CHEM